Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acusphere, Inc.
Acusphere Announces Closing of Transaction with Cephalon
November 21st, 2008
Acusphere, Inc. (NASDAQ: ACUS) announced that it closed its previously announced transaction with Cephalon, Inc., which will provide Acusphere with $20 million in immediate financing through the issuance of a $15 million senior secured convertible note and a $5 million upfront fee for an exclusive worldwide license to AI-525, a preclinical-stage injectable formulation of celecoxib using Acusphere's proprietary Hydrophobic Drug Delivery System (HDDS(TM)) technology. More information about Acusphere's transaction with Cephalon can be found in Acusphere's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 27, 2008 and its Current Report...
Source: Health Business Week (2008-11-21)
|
